A Texas overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
35.6% of Texas adults have obesity, according to the CDC's 2024 BRFSS prevalence estimates 1, above the national adult rate of 33.1% 1. Applied to the state's 31,290,831 residents 2, that prevalence describes roughly 8,688,838 adults — a figure modelled from those two published numbers rather than counted by either agency.
Texas carries almost the same number of adults with obesity as California while having about eight million fewer residents. It also has one of the plainest coverage answers in the country: through the state Medicaid program, weight is not a covered reason to prescribe these drugs.
Nothing about our price is Texan, and that is the point.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
A patient in Amarillo pays what a patient in Houston pays. In a state where the nearest obesity-medicine clinic can be a three-hour drive, distance changes the shipping label and nothing else on the invoice.
Texas Medicaid categorically excludes anti-obesity medications. GLP-1 drugs are reimbursed under the Texas benefit only for diabetes indications, so a member whose indication is weight will not be approved for Wegovy or Zepbound regardless of BMI 3.
Texas sits with the large majority on this: only about ten state Medicaid programs still covered GLP-1s for obesity as of mid-2026 3. Texas is not a state that recently withdrew coverage — there was no obesity benefit to withdraw.
Commercial coverage is where Texans actually see variance, and the employer decides it. A school district, a hospital system, and an energy company headquartered on the same street can land in three different places, because weight-management drug coverage is a benefit each plan sponsor elects or declines.
What to do next: if you are on a Texas public-employee or teacher plan (ERS or TRS), read that plan's current weight-management pharmacy policy directly instead of assuming it matches a commercial plan. If you have private coverage, search your plan-year drug list for Wegovy, Zepbound, and the phrase "weight management", then ask for the prior-authorization criteria if they appear. If weight-loss drugs are excluded, or you are a Texas Medicaid member, the realistic routes are a documented comorbidity appeal, a manufacturer direct-pay program for the branded product, or a cash-pay physician-supervised program such as Astra's.
Yes. Texas law expressly recognizes a practitioner-patient relationship formed through telemedicine: under Texas Occupations Code Chapter 111 4, a licensed provider may evaluate a Texas patient and prescribe non-controlled medications without a prior in-person visit, using synchronous audiovisual technology or another statutorily permitted telemedicine method, and is held to the same standard of care as an in-person visit. Texas Medical Board rules (22 TAC Chapter 175, updated January 2025) 6 require all telemedicine care to comply with Chapter 111 and the Medical Practice Act, and Texas pharmacists may fill telemedicine prescriptions issued through a valid practitioner-patient relationship (Occupations Code Section 562.056) 5. Rules for compounded medications such as semaglutide and tirzepatide are set separately — federally under FDA's Section 503A framework and at the state level by the Texas State Board of Pharmacy's compounding rules 7 — and those rules have continued to change through 2025 and 2026 following FDA's removal of both drugs from its shortage list.
Our provider group holds Texas licensure and our partner pharmacies are licensed to dispense into the state, so a patient in the Rio Grande Valley, West Texas, or the Panhandle can be evaluated and treated at a Texas address without traveling to a metro specialty clinic.
Astra treats patients in Texas through state-licensed physicians.
City pages carry local access context — county figures, clinician supply, and what the local market charges — under the same sourcing rules as this page.
Not for weight loss. Texas Medicaid categorically excludes anti-obesity medications, and GLP-1 drugs are covered only for diabetes indications. As of mid-2026 only about ten state Medicaid programs still covered GLP-1s for obesity.
No, and that is deliberate. Astra charges one price in every state it serves, published once in the cost section above. There is no Texas price list, no regional surcharge, and no local discount.
No. Texas Occupations Code Chapter 111 recognizes a practitioner-patient relationship formed through telemedicine, so a licensed provider may evaluate you and prescribe non-controlled medications without a prior in-person visit, held to the same standard of care as an in-person visit. Texas Medical Board rules in 22 TAC Chapter 175 require that care to comply with Chapter 111 and the Medical Practice Act.
Possibly, but only under narrow conditions. After the FDA declared the tirzepatide and semaglutide shortages resolved (December 2024 and February 2025), compounding pharmacies may no longer routinely produce copies of the approved products; under federal Section 503A, a licensed pharmacy may compound a GLP-1 medication for an individual patient only when the prescriber determines and documents that a compounded formulation presents a clinically significant difference for that patient. Whether that applies to you depends on an evaluation by a licensed provider, and availability is subject to FDA and Texas State Board of Pharmacy rules that continue to evolve.
Tell your care team your new address before your next refill. Treatment is tied to the state you are located in when you are seen, so a provider licensed in your new state has to take over, and the pharmacy has to be licensed to dispense there. If Astra serves your new state we move the plan across without restarting it; if we do not, we say so and stop billing rather than shipping into a state we are not licensed in.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.